Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.61
ELGX's Cash to Debt is ranked higher than
74% of the 315 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.11 vs. ELGX: 1.61 )
ELGX' s 10-Year Cash to Debt Range
Min: 1.22   Max: No Debt
Current: 1.61

Equity to Asset 0.55
ELGX's Equity to Asset is ranked higher than
66% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. ELGX: 0.55 )
ELGX' s 10-Year Equity to Asset Range
Min: 0.41   Max: 0.96
Current: 0.55

0.41
0.96
F-Score: 5
Z-Score: 3.69
M-Score: -3.19
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -13.30
ELGX's Operating margin (%) is ranked higher than
61% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.14 vs. ELGX: -13.30 )
ELGX' s 10-Year Operating margin (%) Range
Min: -237.33   Max: -4.47
Current: -13.3

-237.33
-4.47
Net-margin (%) -14.62
ELGX's Net-margin (%) is ranked higher than
62% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.12 vs. ELGX: -14.62 )
ELGX' s 10-Year Net-margin (%) Range
Min: -228.8   Max: 15.84
Current: -14.62

-228.8
15.84
ROE (%) -17.91
ELGX's ROE (%) is ranked higher than
61% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.62 vs. ELGX: -17.91 )
ELGX' s 10-Year ROE (%) Range
Min: -56.88   Max: 15.58
Current: -17.91

-56.88
15.58
ROA (%) -8.73
ELGX's ROA (%) is ranked higher than
62% of the 316 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.40 vs. ELGX: -8.73 )
ELGX' s 10-Year ROA (%) Range
Min: -50.63   Max: 11.48
Current: -8.73

-50.63
11.48
ROC (Joel Greenblatt) (%) -64.29
ELGX's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 315 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.59 vs. ELGX: -64.29 )
ELGX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1382.35   Max: -22.12
Current: -64.29

-1382.35
-22.12
Revenue Growth (%) 16.60
ELGX's Revenue Growth (%) is ranked higher than
92% of the 284 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.10 vs. ELGX: 16.60 )
ELGX' s 10-Year Revenue Growth (%) Range
Min: -41.8   Max: 66.8
Current: 16.6

-41.8
66.8
EBITDA Growth (%) 73.80
ELGX's EBITDA Growth (%) is ranked higher than
98% of the 240 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.10 vs. ELGX: 73.80 )
ELGX' s 10-Year EBITDA Growth (%) Range
Min: -50   Max: 73.8
Current: 73.8

-50
73.8
» ELGX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ELGX Guru Trades in Q3 2013

Ron Baron 1,288,000 sh (unchged)
Pioneer Investments 447,900 sh (-7.02%)
Steven Cohen 550,165 sh (-39.78%)
» More
Q4 2013

ELGX Guru Trades in Q4 2013

Jim Simons 11,100 sh (New)
Ron Baron 1,288,000 sh (unchged)
Pioneer Investments 394,200 sh (-11.99%)
Steven Cohen 333,802 sh (-39.33%)
» More
Q1 2014

ELGX Guru Trades in Q1 2014

Paul Tudor Jones 17,562 sh (New)
Pioneer Investments 571,453 sh (+44.97%)
Jim Simons Sold Out
Ron Baron Sold Out
Steven Cohen Sold Out
» More
Q2 2014

ELGX Guru Trades in Q2 2014

Pioneer Investments 585,991 sh (+2.54%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ELGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2014-03-31 Sold Out 0.09%$12.52 - $17.9 $ 11.4-27%0
Ron Baron 2012-09-30 Add 71.73%0.05%$11.15 - $15.54 $ 11.4-14%1288000
Ron Baron 2012-06-30 New Buy0.07%$13.21 - $15.27 $ 11.4-20%750000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.28
ELGX's P/B is ranked higher than
61% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.94 vs. ELGX: 5.28 )
ELGX' s 10-Year P/B Range
Min: 1.69   Max: 14.14
Current: 5.28

1.69
14.14
P/S 5.10
ELGX's P/S is ranked higher than
61% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.99 vs. ELGX: 5.10 )
ELGX' s 10-Year P/S Range
Min: 1.14   Max: 53.43
Current: 5.1

1.14
53.43
EV-to-EBIT -57.94
ELGX's EV-to-EBIT is ranked higher than
56% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.34 vs. ELGX: -57.94 )
ELGX' s 10-Year EV-to-EBIT Range
Min: -178.3   Max: -3.3
Current: -57.94

-178.3
-3.3
Current Ratio 5.97
ELGX's Current Ratio is ranked higher than
89% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.78 vs. ELGX: 5.97 )
ELGX' s 10-Year Current Ratio Range
Min: 2.15   Max: 20.25
Current: 5.97

2.15
20.25
Quick Ratio 4.98
ELGX's Quick Ratio is ranked higher than
90% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.82 vs. ELGX: 4.98 )
ELGX' s 10-Year Quick Ratio Range
Min: 2   Max: 19.04
Current: 4.98

2
19.04

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 29.23
ELGX's Price/Net Current Asset Value is ranked higher than
82% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ELGX: 29.23 )
ELGX' s 10-Year Price/Net Current Asset Value Range
Min: 1.05   Max: 1424
Current: 29.23

1.05
1424
Price/Tangible Book 10.56
ELGX's Price/Tangible Book is ranked higher than
65% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.47 vs. ELGX: 10.56 )
ELGX' s 10-Year Price/Tangible Book Range
Min: 0.81   Max: 114.8
Current: 10.56

0.81
114.8
Price/Median PS Value 0.66
ELGX's Price/Median PS Value is ranked higher than
93% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. ELGX: 0.66 )
ELGX' s 10-Year Price/Median PS Value Range
Min: 0.17   Max: 6.23
Current: 0.66

0.17
6.23
Earnings Yield (Greenblatt) -1.70
ELGX's Earnings Yield (Greenblatt) is ranked higher than
61% of the 316 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. ELGX: -1.70 )
ELGX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -1.7

Forward Rate of Return (Yacktman) -1.37
ELGX's Forward Rate of Return (Yacktman) is ranked higher than
68% of the 274 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. ELGX: -1.37 )
ELGX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -39.3   Max: 9.8
Current: -1.37

-39.3
9.8

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:RM1.Germany
Endologix, Inc., was incorporated in California in March 1992 under the name Cardiovascular Dynamics, Inc. and reincorporated in Delaware in June 1993. The Company develops, manufactures, markets and sells innovative treatments for aortic disorders. Its main product is a stent graft and delivery system, for the treatment of abdominal aortic aneurysms ('AAA') through minimally-invasive endovascular repair ('EVAR'). Sales of its ELG System to hospitals in the U.S., and to hospitals and third-party distributors abroad, provide the sole source of its reported revenue. Its ELG System consists of a self-expanding cobalt chromium alloy stent covered by expanded polytetrafluoroethylene graft material; and an accompanying delivery catheter. Once its ELG Device is fixed in its proper position within the abdominal aorta, it provides a conduit for blood flow, thereby relieving pressure within the weakened or 'aneurysmal' section of the vessel wall, which greatly reduces the potential for the AAA to rupture. The Company's ELG System consists of its ELG Device and catheter delivery system, branded under the names AFX, IntuiTrak, and Powerlink. All of its products are manufactured, assembled, packaged and sterilized at its 60,000 square foot leased facility in Irvine, California. It market and sell its ELG System in the U.S. and in several European countries through a direct sales force and network of agents. In certain other European countries and in Asia, South America, and Mexico, it sells its ELG System through exclusive independent distributors. Its main competitors include Medtronic Inc., W.L. Gore Inc., and Cook Medical Products, Inc., Terumo-Vascutek, Trivascular, Aptus, Altura, Cordis, Jotec, Bolton, and Lombard Medical. The Company is subject to other federal, state and local laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices.
» More Articles for ELGX

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: ELGX, LOW, NWS, SBUX, WLP Dec 18 2012 
Endologix Inc Reports Operating Results (10-K) Mar 16 2011 
Endologix Inc Reports Operating Results (10-Q) Nov 08 2010 
Weekly CFO Buys Highlight: FCTOA, GNBT, CTTC, ELGX, ARTC Nov 06 2010 
Endologix Inc Reports Operating Results (10-Q) Jul 30 2010 
Weekly CEO Sells Highlight: Cisco Systems Inc, AmerisourceBergen Corp, PAETEC HOLDING CORP, Endologi May 22 2010 
Endologix Inc (ELGX) CEO John D Mcdermott sells 225,000 Shares May 17 2010 
Endologix Inc Reports Operating Results (10-Q) May 10 2010 
Endologix Inc Reports Operating Results (10-Q) Nov 02 2009 
Endologix Inc Reports Operating Results (10-Q) Jul 28 2009 


More From Other Websites
Endologix meets 3Q profit forecasts Oct 31 2014
Endologix meets 3Q profit forecasts Oct 31 2014
Endologix Inc Earnings Call scheduled for 5:00 pm ET today Oct 30 2014
ENDOLOGIX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition Oct 30 2014
4:10 pm Endologix reports EPS in-line, revs in-line; guides FY14 EPS in-line, revs in-line Oct 30 2014
Endologix Reports 12% Global Revenue Growth for the Third Quarter 2014 Oct 30 2014
Q3 2014 Endologix Inc Earnings Release - After Market Close Oct 30 2014
Endologix to Report Third Quarter 2014 Financial Results on October 30, 2014 Oct 09 2014
Endologix (ELGX) Crumbles: Stock Plunges by 18.2% Sep 30 2014
ENDOLOGIX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Sep 29 2014
Why Endologix (ELGX) Stock Reached a New Low Today Sep 29 2014
Endologix Announces Preliminary Third Quarter 2014 Revenue and Updates Financial Guidance Sep 29 2014
Endologix Completes Enrollment in EVAS FORWARD - Global Registry Sep 29 2014
Endologix to Initiate First Ever Comparative Randomized EVAR Study Sep 29 2014
Analysts At BTIG Confident In Endologix Following Meeting With Top Executives Aug 25 2014
ENDOLOGIX INC /DE/ Financials Aug 08 2014
Endologix Inc Stock Downgraded (ELGX) Aug 06 2014
Endologix to Present at Canaccord Genuity 34th Annual Growth Conference Aug 05 2014
ENDOLOGIX INC /DE/ Files SEC form 10-Q, Quarterly Report Jul 31 2014
ENDOLOGIX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition Jul 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK